Abstract
Cardiovascular and cerebrovascular diseases continue to be leading causes of death throughout the world. Blood platelets play a pivotal role not only in haemostasis but also in the pathogenesis of thrombosis and atherosclerosis, platelet aggregation being an essential step in the formation of either an effective haemostatic plug or an intravascular thrombus. The benefits of various antiplatelet therapies ranging from aspirin, ticlopidine, Clopidogrel, and intravenous platelet GPIIb / IIIa antagonists in various thromboembolic disorders are well documented. Despite of the success of intravenous acute GPIIb / IIIa blockade when given in conjunction with heparin, chronic oral GPIIb / IIIa antagonists with or without aspirin failed in various cardiovascular settings. This review highlights the role of the various antiplatelet therapies in thrombotic disorders as well as future directions.
Keywords: antiplatelet therapies, cerebrovascular diseases, atherosclerosis, intravascular thrombus, clopidogrel, platelet gpIIb/IIIa antagonists, thromboembolic disorders, thrombotic disorders
Current Pharmaceutical Design
Title: Antiplatelet Therapies: Platelet GPIIb / IIIa Antagonists and Beyond
Volume: 9 Issue: 28
Author(s): Shaker A. Mousa
Affiliation:
Keywords: antiplatelet therapies, cerebrovascular diseases, atherosclerosis, intravascular thrombus, clopidogrel, platelet gpIIb/IIIa antagonists, thromboembolic disorders, thrombotic disorders
Abstract: Cardiovascular and cerebrovascular diseases continue to be leading causes of death throughout the world. Blood platelets play a pivotal role not only in haemostasis but also in the pathogenesis of thrombosis and atherosclerosis, platelet aggregation being an essential step in the formation of either an effective haemostatic plug or an intravascular thrombus. The benefits of various antiplatelet therapies ranging from aspirin, ticlopidine, Clopidogrel, and intravenous platelet GPIIb / IIIa antagonists in various thromboembolic disorders are well documented. Despite of the success of intravenous acute GPIIb / IIIa blockade when given in conjunction with heparin, chronic oral GPIIb / IIIa antagonists with or without aspirin failed in various cardiovascular settings. This review highlights the role of the various antiplatelet therapies in thrombotic disorders as well as future directions.
Export Options
About this article
Cite this article as:
Mousa A. Shaker, Antiplatelet Therapies: Platelet GPIIb / IIIa Antagonists and Beyond, Current Pharmaceutical Design 2003; 9 (28) . https://dx.doi.org/10.2174/1381612033453893
DOI https://dx.doi.org/10.2174/1381612033453893 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Multidisciplinary Pharmaceutical Drug Design Strategies in the Progress of Drug Discovery"
The process of developing a drug is time- and money-consuming, but also fascinating. The development of numerous computational techniques, synthetic methodologies, formulation-based drug discovery, etc. has improved the drug discovery process. The process of developing new drugs is significantly hampered by drug-poor pharmacodynamics and pharmacokinetic problems. To address these challenges, ...read more
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employed in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, and prediction, to monitoring of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of T and B Cells in Atherosclerosis: Potential Clinical Implications
Current Pharmaceutical Design p38 Mitogen-Activated Protein Kinase: A Critical Node Linking Insulin Resistance and Cardiovascular Diseases in Type 2 Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets Oral Appliances Improve Sleep Quality in Japanese Patients with Obstructive Sleep Apnea
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) EPO Relies upon Novel Signaling of Wnt1 that Requires Akt1, FoxO3a,GSK-3β, and β-Catenin to Foster Vascular Integrity during Experimental Diabetes
Current Neurovascular Research Molecular Basis of Cardioprotection by Erythropoietin
Current Molecular Pharmacology Vitamin D Supplementation: A Promising Approach for the Prevention and Treatment of Strokes
Current Drug Targets Renin Angiotensin System as a Regulator of Cell Volume. Implications to Myocardial Ischemia
Current Cardiology Reviews Potential Role of microRNAs in Cardiovascular Disease: Are They up to Their Hype?
Current Cardiology Reviews Dysfunctions of the Diffusional Membrane Pathways Mediated Hemichannels in Inherited and Acquired Human Diseases
Current Vascular Pharmacology Relaxin as a Cardiovascular Drug: A Promise Kept
Current Drug Safety Mechanisms of Enhanced Vasoconstriction in the Mouse Model of Atherosclerosis: the Beneficial Effects of Sildenafil
Current Pharmaceutical Biotechnology Sirtuins: Possible Clinical Implications in Cardio and Cerebrovascular Diseases
Current Drug Targets Acute Myocardial Infarction: High Risk Ventricular Tachyarrhythmias and Admission Glucose Level in Patients with and without Diabetes Mellitus
Current Diabetes Reviews Network Pharmacology, Molecular Docking Analysis and Molecular Dynamics Simulation of <i>Scutellaria baicalensis</i> in the Treatment of Liver Fibrosis
Current Pharmaceutical Design Hemolytic Uremic Syndrome in Children
Current Pediatric Reviews Cell Therapy for the Treatment of Chronic Ischemic Heart Disease
Current Pharmaceutical Design Omega-3 Fatty Acids: Role in Metabolism and Cardiovascular Disease
Current Pharmaceutical Design Vasospastic Angina and Ca Channel Blockers
Current Hypertension Reviews Clinical Applications of Positron Emission Tomography (PET) Imaging in Medicine: Oncology, Brain Diseases and Cardiology
Current Radiopharmaceuticals Irreversible Inhibition of Serine Proteases – Design and In Vivo Activity of Diaryl α-Aminophosphonate Derivatives
Current Medicinal Chemistry